A Case of Malignant Lymphomas that Healed Completely After Oral Administrations of 4-Hydroxybenzaldehyde
Journal Title: Open Access Journal of Oncology and Medicine - Year 2018, Vol 1, Issue 5
Abstract
In 1969, Mutsuyuki Kochi [1,2] developed 4-Hydroxybenzaldehyde for use as a novel anti-tumor agent without side effect and acquired its patent. Accordingly, this medicine is capable of preventing carcinogenesis when used in sufficient quantity. To treat advanced cancers, an oncologist should start with giving the cancer patient a small dose of the 4-Hydroxybenzaldehyde to avoid the possible severe hemorrhage of a tumor caused by excessive necrosis. Therefore, it has useful applications in treating lymphomas and leukemia’s. Consequently, those who have these diseases can receive a considerably large dose of the medicine. The mechanism of action of the medicine is apparently competitive inhibition of tyrosine kinase, which is the rate-limiting enzyme in the pathway of carcinogenesis [3,4]. A 45-year-old woman (Y.Y.) visited the author’s clinic on August 7, 2014. She said that she had been diagnosed to have a malignant lymphoma of 3cm-diameter at the right side of her clavicular cavity and another one of 1cm-diameter at the right side of her neck at Mitsuhashi Gynecological Clinic in Kohriyama City, Nara Prefecture on June 20, 2014. At the author’s clinic, she was prescribed with daily 83mg (17ml of 5mg/ml aqueous solution) of 4-Hydroxybenzaldehyde during the period from August 8, 2014 until December 8, 2014. The daily dose was raised to 111mg (22ml of 5mg/ml aqueous solution) during the period from December 9, 2014 until March 8, 2015. The daily dose was raised to 167mg (33ml of 5mg/ml aqueous solution) during the period from March 9, 2015 to May 13, 2015. The daily dose was raised to 222mg (44ml of 5mg/ml aqueous solution) during the period from May 14, 2015 to August 11, 2015. The daily dose was raised to 333mg (67ml of 5mg/ml aqueous solution) during the period from August 12, 2015 to September 13, 2015.
Authors and Affiliations
Kimihiko Okazaki
Keywords
Related Articles
- EP ID EP587885
- DOI 10.32474/OAJOM.2018.01.000124
- Views 75
- Downloads 0
Repurposed Drugs and Nutraceutical Supplements as Neglected Complements to Cancer Treatment
In ovarian cancer there is formation of tumor cells in ovarian tissues. Lysophosphatidic acid (LPA) motivated cell proliferation, migration and endurance by acting on its cognate G-protein-coupled receptors. Lysophosphat...
Central Nervous System Manifestation of Multiple Myeloma: A Case Report
Multiple myeloma accounts for <1% of all malignancies and Central nervous system (CNS) manifestation of multiple myeloma (MM) is rare. Multiple myelomais characterized by malignant transformation of plasma cells that pro...
A Note on Mushroom Immunomodulation and its Potential on Prevention of Cancer
Patterns of diseases and resulting well-being, morbidity and mortality have changed considerably in the last decades namely in developed countries. Infection-contagious diseases are no longer a major threat and other chr...
Librarians who Request for Reprints Including those in Oncology
A 13-year retrospective study of reprint requestors was undertaken with special reference to those from research libraries. It was found that 2.8 percent of the total 2,053 requests were from such librarians. They prepon...
Promising Role of Fractional Calculus in Biomedicine and Biophysics
The study of complex systems and investigation of their structural and dynamical properties have attracted considerable interests among scientists in general and physicists, biologists and medical researchers in particul...